Loading clinical trials...
Loading clinical trials...
Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With Relapsing-remitting and Secondary-progressive Multiple Sclerosis
Conditions
Interventions
Avonex® monotherapy (6.0 MIU administered i.m. each week)
Locations
1
United States
The Jacobs Neurological Institute
Buffalo, New York, United States
Start Date
June 1, 2005
Completion Date
September 1, 2006
Last Updated
December 28, 2020
NCT06276634
NCT07225504
NCT06809192
NCT05359653
NCT07426991
NCT07376772
Lead Sponsor
State University of New York at Buffalo
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions